What is the Market's View on Checkpoint Therapeutics Inc (CKPT) Stock's Price and Volume Trends Wednesday?

Checkpoint Therapeutics Inc (CKPT) stock is higher by 4.62% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Checkpoint Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CKPT!

See Full CKPT Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CKPT Stock Today?

Checkpoint Therapeutics Inc (CKPT) stock is trading at $2.49 as of 11:37 AM on Wednesday, Jan 26, a rise of $0.03, or 1.22% from the previous closing price of $2.46. Volume today is elevated. So far 2,264,129 shares have traded compared to average volume of 1,680,268 shares. The stock has traded between $2.42 and $2.58 so far today. To see InvestorsObserver's Sentiment Score for Checkpoint Therapeutics Inc click here.

More About Checkpoint Therapeutics Inc

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Click Here to get the full Stock Report for Checkpoint Therapeutics Inc stock.